ReviewFrontiers in immunology2026
Osteoimmune senescence in aging-related bone diseases.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aging-related bone diseases are increasingly recognized as disorders in which uncoupled bone remodeling remains central but is substantially modified by immune-skeletal interactions. This review consolidates current evidence for osteoimmune senescence, a framework that links senescent skeletal cells, aging immune compartments, chronic SASP signaling, impaired immune clearance, and marrow-niche deterioration to reduced bone strength and repair. Osteoporosis, rheumatoid arthritis-associated erosion, osteoarthritis, periodontal bone loss, and delayed fracture healing are clinically distinct diseases, but they may share overlapping senescence-associated osteoimmune mechanisms while retaining disease-specific endotypes. Senescent osteocytes, osteoblast-lineage cells, and bone marrow stromal cells can increase RANKL/OPG imbalance, suppress osteogenesis, and reshape immune recruitment, whereas remodeled T cells, macrophages, neutrophils, and NK-cell surveillance pathways modify osteoclastogenesis and repair resolution. We also discuss gut-derived metabolites and imaging phenotypes as clinically important but non-specific readouts of this biology. DXA, HR-pQCT, MRI, CBCT, and molecular imaging cannot identify senescent cells directly, but they can anchor molecular hypotheses to tissue-level deterioration. Therapeutic translation will depend on matching senolytics, senomorphics, immune-recalibrating approaches, microbiota-derived metabolites, and bone-targeted delivery systems to disease stage, dominant cell population, and measurable skeletal endpoints.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.